- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
- Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
- Fulcrum Therapeutics to Participate in Upcoming May Conferences
- Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
- Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
- Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
More ▼
Key statistics
On Thursday, Fulcrum Therapeutics Inc (FULC:NMQ) closed at 7.80, 194.15% above the 52 week low of 2.65 set on Jun 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.32 |
---|---|
High | 8.32 |
Low | 7.74 |
Bid | 7.56 |
Offer | 8.49 |
Previous close | 7.80 |
Average volume | 626.23k |
---|---|
Shares outstanding | 62.15m |
Free float | 61.29m |
P/E (TTM) | -- |
Market cap | 484.49m USD |
EPS (TTM) | -1.61 USD |
Data delayed at least 15 minutes, as of May 16 2024 21:00 BST.
More ▼